|
Parameter
|
Cohort (n = 70)
|
|---|
|
Patients-no.
|
70
|
|
Tumors (targets)-no.
|
76
|
|
Follow-up time-median (range)
|
15 (8–22) months
|
|
Median age-median (range)
|
74 (54–91) years
|
|
Sex
| |
|
M-no. (%)
|
28 (40.0)
|
|
F-no. (%)
|
42 (60.0)
|
|
Location
| |
|
Right upper lobe-no. (%)
|
18 (23.7)
|
|
Right middle lobe-no. (%)
|
4 (5.3)
|
|
Right lower lobe-no. (%)
|
14 (18.4)
|
|
Left upper lobe-no. (%)
|
14 (18.4)
|
|
Left lower lobe-no. (%)
|
26 (34.2)
|
|
Central
|
28 (36.8)
|
|
Peripheral
|
48 (63.2)
|
|
Metastatic-no. (%)
|
2 (2.9)
|
|
Lung Primary-no. (%)
|
68 (97.1)
|
|
Histology
| |
|
Adenocarcinoma
|
40 (57.1)
|
|
Squamous
|
17 (24.3)
|
|
NSCLC-NOS
|
11 (15.7)
|
|
Tumor Size-median (range)
|
2.3 (0.6–5.5) cm
|
|
≤3 cm
|
53 (69.7)
|
|
>3 cm
|
23 (30.3)
|
|
Median GTV (range)
|
6.6 (0.3–150.4) cc
|
|
Median PTV (range)
|
20.8 (12.4–308.2) cc
|
|
Median total dose (range)
|
50 (25–60) Gy
|
|
1 fraction (%)
|
19 (27.1 %)
|
|
3–8 fractions (%)
|
51 (72.9 %)
|
-
Abbreviations: NSCLC non-small-cell lung cancer, NOS Not otherwise specified, GTV gross tumor volume, PTV planning target volume
